A Phase II Study of Autologous Stem Cell Transplant and Lenalidomide with or without a Personalized Vaccine to Treat Multiple Myeloma

Full Title

Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell (DC)/Myeloma Fusions (BMT CTN 1401)


Using a patient’s own blood-forming cells (special cells called “stem cells”) to help increase blood counts after high doses of chemotherapy is called autologous stem cell transplantation (ASCT). ASCT is a treatment approach for patients with multiple myeloma. Patients may also receive “maintenance therapy” with a drug called lenalidomide to reduce the chance that the myeloma will come back.

In this study, researchers want to know if adding an investigational anticancer vaccine can help make this treatment even more effective. The vaccine is made from a patient’s own dendritic cells, a special type of white blood cell that triggers immune responses. Patients in this study will receive ASCT plus lenalidomide with or without the personalized cancer vaccine. Some patients will also receive GM-CSF, a drug that can help boost the immune system.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that is causing symptoms.
  • Patients must be eligible to receive ASCT.
  • This study is for patients age 18-70.

For more information about this study and to inquire about eligibility, please contact Dr. David Chung at 212-639-6617.